Parexel Appoints Keri Mattox As Chief Business Officer

Parexel, one of the world’s largest clinical research organisations (CROs), has appointed Keri Mattox to the newly created position of Chief Business Officer. In her new role,  Mattox will oversee the company’s business operations and spearhead its growth strategy. With over 25 years of experience in healthcare, including corporate strategy, investor relations, and environmental, social, and governance (ESG) initiatives, Mattox will play a pivotal role in Parexel’s expansion and report directly to CEO Peyton Howell.

“I’m thrilled to join Parexel at this exciting phase of its growth,” said Mattox. “The company’s commitment to operational excellence and patient-centered solutions is evident, and I look forward to contributing to its continued success and innovation.”

Before joining Parexel, Mattox held key leadership roles at Zimmer Biomet, W2O Group, and AmerisourceBergen, among others. Her expertise is expected to significantly contribute to Parexel’s strategic transformation.

Peyton Howell, Parexel’s CEO, stated, “We’re excited to welcome Keri to Parexel. Her leadership and deep industry expertise will be invaluable as we continue to grow and innovate.”